Supplementary material: Appendix list of excluded articles after full text review and reasons for exclusion:

- Studies addressing domains in quality of life or psychological satisfaction not related to treatment adherence or treatment utilization

Bian W, Wan J, Smith G, Li S, Tan M, Zhou F. Domains of health-related quality of life in age-related macular degeneration: A qualitative study in the Chinese cultural context. BMJ Open. 2018;8(4).

Spooner K, Mhlanga C, Hong T, Broadhead G, Chang A. The burden of neovascular age-related macular degeneration. Clinical and Experimental Ophthalmology. 2018;46:119-20.

Varano M, Eter N, Winyard S, Wittrup-Jensen KU, Navarro R, Heraghty J. The emotional and physical impact of wet age-related macular degeneration: Findings from the wAMD patient and Caregiver Survey. Clinical Ophthalmology. 2016;10:257-67.

- Studies addressing patients' experiences without addressing the impact or correlation with adherence/persistence or barriers to treatment.

Baxter JM, Fotheringham AJ, Foss AJ. Determining patient preferences in the management of neovascular age-related macular degeneration: a conjoint analysis. Eye (London, England). 2016;30(5):698-704.

Boyle J, Vukicevic M, Koklanis K, Itsiopoulos C. Experiences of patients undergoing anti-VEGF treatment for neovascular age-related macular degeneration: a systematic review. Psychology, health & medicine. 2015;20(3):296-310.

Chua PY, Mitrut I, Armbrecht AM, Vani A, Aslam T, Dhillon B. Evaluating patient discomfort, anxiety, and fear before and after ranibizumab intravitreous injection for wet age-related macular degeneration. Archives of ophthalmology (Chicago, Ill : 1960). 2009;127(7):939-40.

DaCosta J, Hamilton R, Nago J, Mapani A, Kennedy E, Luckett T, et al. Implementation of a nurse-delivered intravitreal injection service. Eye (London, England). 2014;28(6):734-40.

Droege KM, Caramoy A, Kersten A, Luberichs-Fauser J, Zilkens K, Muller D, et al. Patient preference of ranibizumab treatment regimen for neovascular age-related macular degeneration - monthly injections versus pro re nata. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2014;252(1):31-4.

Emsfors A, Christensson L, Elgan C. Nursing actions that create a sense of good nursing care in patients with wet age-related macular degeneration. Journal of clinical nursing. 2017;26(17-18):2680-8.

Ferreira A, Lall A, Squire A, Gregg L, Graham A. Patient preferences regarding monitoring and treatment for the management of neovascular age-related macular degeneration. Value in Health. 2013;16(7):A508.

Framme C, Wolf-Schnurrbusch UE, Lobsiger H, Bayer S, Wolf S. [Adapted and standardised patient management in the treatment of neovascular AMD in the outpatient setting of a university eye hospital]. Klin Monbl Augenheilkd. 2012;229(8):812-21.

Gallagher MJ. Introduction of a nurse-led intravitreal injection service in ophthalmology. British journal of nursing (Mark Allen Publishing). 2017;26(14):800-3.

Gohil R, Crosby-Nwaobi R, Forbes A, Burton B, Hykin P, Sivaprasad S. Caregiver Burden in Patients Receiving Ranibizumab Therapy for Neovascular Age Related Macular Degeneration. PLoS One. 2015;10(6):e0129361.

Gregg E. Nurse-led ranibizumab intravitreal injections in wet age-related macular degeneration: a literature review. Nursing standard (Royal College of Nursing (Great Britain): 1987). 2017;31(33):44-52.

Hasan H, Flockhart S, Qureshi W, Khan S, Ahmed S, Shah N. Intravitreal injections service: a patient experience evaluation. British journal of nursing (Mark Allen Publishing). 2017;26(12):678-82.

Jelin E, Wisloff T, Moe MC, Heiberg T. Development and testing of a patient-derived questionnaire for treatment of neovascular age-related macular degeneration: dimensions of importance in treatment of neovascular age-related macular degeneration. Acta Ophthalmol. 2018;96(8):804-11.

Kayikcioglu O, Bilgin S, Seymenoglu G, Deveci A. State and trait anxiety scores of patients receiving intravitreal injections. Biomedicine Hub. 2017;2(2).

Kostadinov F, Valmaggia C. [Disease perception in patients with wet age-related macular degeneration]. Klin Monbl Augenheilkd. 2015;232(4):525-8.

Li E, Greenberg PB, Krzystolik MG. Nurse-administered intravitreal injections: a systematic review. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2015;253(9):1619-21.

Mapani A, Khan Y. Patient satisfaction with nurse delivered intravitreal injections. Investigative Ophthalmology and Visual Science. 2016;57(12):3345.

McCloud C, Khadka J, Gilhotra JS, Pesudovs K. Divergence in the lived experience of people with macular degeneration. Optometry and vision science : official publication of the American Academy of Optometry. 2014;91(8):966-74.

McCloud C, Lake S. Understanding the patient's lived experience of neovascular age-related macular degeneration: a qualitative study. Eye (London, England). 2015;29(12):1561-9.

Mueller S, Agostini H, Ehlken C, Bauer-Steinhusen U, Hasanbasic Z, Wilke T. Patient Preferences in the Treatment of Neovascular Age-Related Macular Degeneration: A Discrete Choice Experiment. Ophthalmology. 2016;123(4):876-83.

Muller S, Ehlken C, Bauer-Steinhusen U, Lechtenfeld W, Hasanbasic Z, Agostini H, et al. Treatment of age-related neovascular macular degeneration: the patient's perspective. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2017;255(11):2237-46.

Prenner JL, Halperin LS, Rycroft C, Hogue S, Williams Liu Z, Seibert R. Disease Burden in the Treatment of Age-Related Macular Degeneration: Findings From a Time-and-Motion Study. Am J Ophthalmol. 2015;160(4):725-31.e1.

Rodriguez Ramirez M, del Barrio Manso MI, Martin Sanchez MD. Intravitreal injections: what do patients prefer? Analysis of patient's satisfaction and preferences about where to perform intravitreal injections. Archivos de la Sociedad Espanola de Oftalmologia. 2014;89(12):477-83.

Santiago C, Ngai LY, McKenzie R. Evaluation of the one stop age related macular degeneration (AMD) service in the North East of Scotland. Ophthalmologica. 2016;236:19.

Senra H, Balaskas K, Mahmoodi N, Aslam T. Experience of Anti-VEGF Treatment and Clinical Levels of Depression and Anxiety in Patients With Wet Age-Related Macular Degeneration. Am J Ophthalmol. 2017;177:213-24.

Senra H, Ali Z, Balaskas K, Aslam T. Psychological impact of anti-VEGF treatments for wet macular degeneration-a review. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2016;254(10):1873-80.

Skelly A, Kommineni J, Rai N, Banhazi J. Leveraging social media to explore patient experiences in neovascular age-related macular degeneration. Value in Health. 2018;21:S242.

Tailor R, Beasley R, Yang Y, Narendran N. Evaluation of patients' experiences at different stages of the intravitreal injection procedure - what can be improved? Clinical ophthalmology (Auckland, NZ). 2011;5:1499-502.

Vennedey V, Danner M, Evers SM, Fauser S, Stock S, Dirksen CD, et al. Using qualitative research to facilitate the interpretation of quantitative results from a discrete choice experiment: insights from a survey in elderly ophthalmologic patients. Patient Prefer Adherence. 2016;10:993-1002.

Gohil R, Crosby-Nwaobi R, Forbes A, Burton BJ, Hykin P, Sivaprasad S. Treatment satisfaction of patients undergoing ranibizumab therapy for neovascular age-related macular degeneration in a real-life setting. Patient Prefer Adherence. 2016;10:949-55.

Kandula S, Lamkin JC, Albanese T, Edward DP. Patients' knowledge and perspectives on wet age-related macular degeneration and its treatment. Clinical ophthalmology (Auckland, NZ). 2010;4:375-81.

- Studies describing physicians' preferences and patients' experiences but without addressing the impact or correlation with adherence/persistence

Williams ZY, Prenner JL, Halperin LS, Hogue S, Seibert R. Burden of illness in the management of age-related macular degeneration: Findings from a time-and-motion study. Value in Health. 2014;17(3):A287.

- Studies reporting on strategies to improve patients' experiences/satisfaction but without addressing the impact or correlation with adherence/persistence

Chaudhary V, Gusenbauer K, Mak M, Barbosa J, Mohammad Mohaghegh PS, Popovic M. Waiting room educational media effect on preinjection anxiety for initial intravitreal injections. Canadian journal of ophthalmology Journal canadien d'ophtalmologie. 2016;51(2):71-5.

Cohen SM, Billiris-Findlay K, Eichenbaum DA, Pautler SE. Topical lidocaine gel with and without subconjunctival lidocaine injection for intravitreal injection: A within-patient study. Ophthalmic Surgery Lasers and Imaging. 2014;45(4):306-10.

Guler M, Bilgin B, Capkin M, Simsek A, Bilak S. Assessment of patient pain experience during intravitreal 27-gauge bevacizumab and 30-gauge ranibizumab injection. Korean journal of ophthalmology : KJO. 2015;29(3):190-4.

Haas P, Falkner-Radler C, Wimpissinger B, Malina M, Binder S. Needle size in intravitreal injections - pain evaluation of a randomized clinical trial. Acta Ophthalmol. 2016;94(2):198-202.

Ratnarajan G, Nath R, Appaswamy S, Watson SL. Intravitreal injections using a novel conjunctival mould: a comparison with a conventional technique. The British journal of ophthalmology. 2013;97(4):395-7.

van Asten F, van Middendorp H, Verkerk S, Breukink MB, Lomme RM, Hoyng CB, et al. Are intravitreal injections with ultrathin 33-g needles less painful than the commonly used 30-g needles? Retina. 2015;35(9):1778-85.

Yau GL, Jackman CS, Hooper PL, Sheidow TG. Intravitreal injection anesthesia--comparison of different topical agents: a prospective randomized controlled trial. Am J Ophthalmol. 2011;151(2):333-7.e2.

- Studies assessing contributors to caregiver burden but without addressing the impact or correlation with adherence/persistence

Gohil R, Crosby-Nwaobi R, Forbes A, Burton B, Hykin P, Sivaprasad S. Caregiver Burden in Patients Receiving Ranibizumab Therapy for Neovascular Age Related Macular Degeneration. PLoS One. 2015;10(6):e0129361.

- Studies not providing results for nAMD

DaCosta J, Hamilton R, Nago J, Mapani A, Kennedy E, Luckett T, et al. Implementation of a nurse-delivered intravitreal injection service. Eye (London, England). 2014;28(6):734-40.

Gallagher MJ. Introduction of a nurse-led intravitreal injection service in ophthalmology. British journal of nursing (Mark Allen Publishing). 2017;26(14):800-3.

Hasan H, Flockhart S, Qureshi W, Khan S, Ahmed S, Shah N. Intravitreal injections service: a patient experience evaluation. British journal of nursing (Mark Allen Publishing). 2017;26(12):678-82.

Jelin E, Wisloff T, Moe MC, Heiberg T. Development and testing of a patient-derived questionnaire for treatment of neovascular age-related macular degeneration: dimensions of importance in treatment of neovascular age-related macular degeneration. Acta Ophthalmol. 2018;96(8):804-11.

Kayikcioglu O, Bilgin S, Seymenoglu G, Deveci A. State and trait anxiety scores of patients receiving intravitreal injections. Biomedicine Hub. 2017;2(2).

Li E, Greenberg PB, Krzystolik MG. Nurse-administered intravitreal injections: a systematic review. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2015;253(9):1619-21.

Mapani A, Khan Y. Patient satisfaction with nurse delivered intravitreal injections. Investigative Ophthalmology and Visual Science. 2016;57(12):3345.

Chaudhary V, Gusenbauer K, Mak M, Barbosa J, Mohammad Mohaghegh PS, Popovic M. Waiting room educational media effect on preinjection anxiety for initial intravitreal injections. Canadian journal of ophthalmology Journal canadien d'ophtalmologie. 2016;51(2):71-5.

Cohen SM, Billiris-Findlay K, Eichenbaum DA, Pautler SE. Topical lidocaine gel with and without subconjunctival lidocaine injection for intravitreal injection: A within-patient study. Ophthalmic Surgery Lasers and Imaging. 2014;45(4):306-10.

Guler M, Bilgin B, Capkin M, Simsek A, Bilak S. Assessment of patient pain experience during intravitreal 27-gauge bevacizumab and 30-gauge ranibizumab injection. Korean journal of ophthalmology : KJO. 2015;29(3):190-4.

Haas P, Falkner-Radler C, Wimpissinger B, Malina M, Binder S. Needle size in intravitreal injections - pain evaluation of a randomized clinical trial. Acta Ophthalmol. 2016;94(2):198-202.

Alattas K. Patients' tolerance of bimanual lid retraction versus a metal speculum for intravitreal injections. Clinical ophthalmology (Auckland, NZ). 2016;10:1719-21.

Andrade GC, Carvalho AC. Comparison of 3 different anesthetic approaches for intravitreal injections: a prospective randomized trial. Arquivos brasileiros de oftalmologia. 2015;78(1):27-31.

Fiebai B, Odogu V. Intravitreal Anti Vascular Endothelial Growth Factor Agents in The Management of Retinal Diseases: An Audit. The open ophthalmology journal. 2017;11:315-21.

Cordeiro Sousa D, Leal I, Fonseca AF, Marques-Neves C. Portuguese retinal practices-PRP survey. Ophthalmic Research. 2018;60(2):127.

Ern Hui Fang C, Murtagh P, Kinsella F. Introduction of intravitreal injection booklet in university college hospital Galway. Irish Journal of Medical Science. 2018;187(2):S11-S2.

Raguro A, Bisain L, Gencheva P, Chandran M, Laginaf M, Nair N, et al. Implementation and evaluation of a nurse-delivered intravitreal injection service. Investigative Ophthalmology and Visual Science. 2015;56(7):4175.

- Studies addressing neither patients’ preferences/satisfaction nor reasons/correlates for adherence/persistence

Bouws J, Pauleikhoff D, Lemmen KD, Heimes B, Adolphs C. [Analysis of Anti-VEGF Intravitreal Injection Treatment in Clinical Practice]. Klin Monbl Augenheilkd. 2016;233(9):1049-55.

Cohen SY, Mimoun G, Oubraham H, Zourdani A, Malbrel C, Quere S, et al. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study. Retina. 2013;33(3):474-81.

Dougherty BE, Cooley SSL, Segerstrom E, Davidorf FH. Potential mediators of the relationship between socioeconomic status and vision in people with age-related macular degeneration. Investigative Ophthalmology and Visual Science. 2017;58(8).

El-Mollayess GM, Mahfoud Z, Schakal AR, Salti HI, Jaafar D, Bashshur ZF. Fixed-interval versus OCT-guided variable dosing of intravitreal bevacizumab in the management of neovascular age-related macular degeneration: a 12-month randomized prospective study. Am J Ophthalmol. 2012;153(3):481-9.e1.

Eldem BM, Muftuoglu G, Topbas S, Cakir M, Kadayifcilar S, Ozmert E, et al. A randomized trial to compare the safety and efficacy of two ranibizumab dosing regimens in a Turkish cohort of patients with choroidal neovascularization secondary to AMD. Acta Ophthalmol. 2015;93(6):e458-64.

Finger R, Fotis K, Cummins R, Heraghty J, Guymer R. Anti-VEGF treatment for neovascular age-related macular degeneration in Australia. Clinical and Experimental Ophthalmology. 2014;42:14.

Finger RP, Hoffmann AE, Fenwick EK, Wolf A, Kampik A, Kernt M, et al. Patients' preferences in treatment for neovascular age-related macular degeneration in clinical routine. The British journal of ophthalmology. 2012;96(7):997-1002.

Finger RP, Holz FG. [Access to healthcare services for elderly patients with neovascular age-related macular degeneration]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft. 2012;109(5):474-8.

Finger RP, Xie J, Fotis K, Parikh S, Cummins R, Mitchell P, et al. Disparities in access to anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration. Clinical & experimental ophthalmology. 2017;45(2):143-51.

Giocanti-Auregan A, Chbat E, Darugar A, Morel C, Morin B, Conrath J, et al. Influence of new societal factors on neovascular age-related macular degeneration outcomes. BMC ophthalmology. 2018;18(1):22.

Jaffe DH, Chan W, Bezlyak V, Skelly A. The economic and humanistic burden of patients in receipt of current available therapies for nAMD. Journal of comparative effectiveness research. 2018;7(11):1125-32.

McCloskey C, Horgan N. An audit on the time interval from diagnosis of wet age-related macular degeneration (ARMD) to treatment initiation with anti-VEGF intravitreal injections. Irish Journal of Medical Science. 2015;184(7):S261-S2.

Musch DC. Anti-VEGF Neovascular Age-Related Macular Degeneration Treatment Adherence Requires Attention and Action. JAMA Ophthalmol. 2018;136(11):1260-1.

Nguyen V, Daien V, Guymer R, McAllister I, Morlet N, Barthelmes D, et al. Social and clinical characteristics associated with low visual acuity at presentation of AMD. Investigative Ophthalmology and Visual Science. 2017;58(8).

Rac K, Lee G. Patient-reported outcome and ex perience measures in macular degeneration and glaucoma. Clinical and Experimental Ophthalmology. 2015;43:104-5.

Taylor J, Scott LJ, Rogers CA, Muldrew A, O'Reilly D, Wordsworth S, et al. The design and implementation of a study to investigate the effectiveness of community vs hospital eye service follow-up for patients with neovascular age-related macular degeneration with quiescent disease. Eye (London, England). 2016;30(1):68-78.

Vaze A, Fraser-Bell S, Gillies M. Consequences of long-term discontinuation of vascular endothelial growth factor inhibitor therapy in the patients with neovascular age-related macular degeneration. Acta Ophthalmol. 2014;92(8):e697-8.

Wilke RGH, Sachs HG. Adherence to treatment determines 5-year outcome in neovascular AMD in a real-life setting. Investigative Ophthalmology and Visual Science. 2016;57(12):3362.

Yang Y, Downey L, Mehta H, Mushtaq B, Narendran N, Patel N, et al. Resource Use and Real-World Outcomes for Ranibizumab Treat and Extend for Neovascular Age-Related Macular Degeneration in the UK: Interim Results from TERRA. Ophthalmol Ther. 2017;6(1):175-86.

- Studies describing adherence or discontinuation/noncompliance rates but without exploring reasons or barriers

Pagliarini S, Beatty S, Lipkova B, Perez-Salvador Garcia E, Reynders S, Gekkieva M, et al. A 2-Year, Phase IV, Multicentre, Observational Study of Ranibizumab 0.5 mg in Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice: The EPICOHORT Study. Journal of ophthalmology. 2014;2014:857148.

Sachs HG, Wilke RG. [Anti VEGF Therapy Under Real-Life Conditions: Adherance Determines Long Term Outcome in Neovascular AMD]. Klin Monbl Augenheilkd. 2016;233(8):958-64.

- Conference abstracts without enough information to allow assessment of adherence or persistence issues, including patients' experiences that would impact these outcomes

Boyle J, Vukicevic M, Koklanis K, Itsiopoulos C, Rees G. The psychosocial impact of repeated intravitreal injections on patients with neovascular age-related macular degeneration. Clinical and Experimental Ophthalmology. 2014;42:110.

Chen J, Schwartz SD, Sarraf D, Tsui I. Anti-VEGF therapy utilization for neovascular age-related macular degeneration in a regional veterans affairs medical center. Investigative Ophthalmology and Visual Science. 2015;56(7):1497.

Sander B, Rasmussen A, Lund-Andersen H. Visual outcome following treatment with aflibercept in patients with neovascular age-related macular degeneration. Acta Ophthalmologica. 2015;93.

Hopkins JJ, Regillo CD, Osborne A, Francom SF, Barteselli G. Sustained delivery of Ranibizumab: The LADDER trial of the Ranibizumab port delivery system. Investigative Ophthalmology and Visual Science. 2016;57(12):530.